Phase 2 Type 1 Diabetes Trial, Recruiting (NCT06976619)

Phase 2 Type 1 Diabetes Trial, Recruiting NCT06976619 Sponsor: Mayo Clinic Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06976619 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have type 1 or type 2 diabetes and are currently being treated with insulin

Who may not be able to join:

People who are younger than 25 or older than 70 years of age
People whose HbA1c blood sugar level is above 10.0% (this is a measure of average blood sugar over several months — confirm with trial site)
Women who test positive for pregnancy at the time of joining the trial
People who have previously had certain upper abdominal surgeries, such as gastric banding, pyloroplasty, or vagotomy
People who have used a type of diabetes medication called GLP-1 receptor agonists at any point in the past year
People who currently have an active serious illness or cancer
People who have symptoms related to complications affecting large or small blood vessels, such as heart disease or nerve and kidney damage (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Adrian Vella, MD, Mayo Clinic

Phone: 507-255-6515

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06976619

Sponsor: Mayo Clinic

Phase: Phase 2

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: 507-255-6515

More information: https://clinicaltrials.gov/study/NCT06976619

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have type 1 or type 2 diabetes and are currently being treated with insulin

Who may not be able to join:

People who are younger than 25 or older than 70 years of age
People whose HbA1c blood sugar level is above 10.0% (this is a measure of average blood sugar over several months — confirm with trial site)
Women who test positive for pregnancy at the time of joining the trial
People who have previously had certain upper abdominal surgeries, such as gastric banding, pyloroplasty, or vagotomy
People who have used a type of diabetes medication called GLP-1 receptor agonists at any point in the past year
People who currently have an active serious illness or cancer
People who have symptoms related to complications affecting large or small blood vessels, such as heart disease or nerve and kidney damage (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

3 October 2025

Est. completion

30 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment; Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia before and after liraglutide

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov